Clinical trial
A Randomised, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients With Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC)
NCT01507168 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients With Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 2, 2012
- Completion date
- August 20, 2015
- Enrollment
- 185 (actual)
- Sites
- 57
Conditions
As the registry lists them; a condition with its own page is linked.